Intraperitoneal Chemotherapy
FASN for diffuse malignant peritoneal mesothelioma: a prognostic biomarker after CRS+HIPEC and a therapeutic target
Journal of Translational Medicine 2026 May 21 [Link] Valentina Doldi, Chiara Maura Ciniselli, Claudia Aurelio, Enrica Favini, Silvio Marco Veronese, Fabio Bozzi, Shigeki Kusamura, Dario Baratti, Silvia Martini, Paolo Verderio, Marcello Deraco, Marco Folini, Paolo Gandellini, Sandro Pasquali, Nadia Zaffaroni Abstract Background: Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive malignancy with limited…
Read MorePIPAC for Malignant Peritoneal Mesothelioma: Current Insights and Future Directions
Digestive Surgery 2026 May 12 [Link] Arianna Castagna, Aphrodite Fotiadou, Ali Ramouz, Preslava Gesheva, Niall Brindl, Wiebke Solass, Andreas Brandl Abstract Malignant peritoneal mesothelioma (MPM) is a rare and aggressive tumour with poor prognosis, often diagnosed late due to nonspecific symptoms. Current standard treatment involves systemic chemotherapy and cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy…
Read MoreMET amplification in diffuse pleural mesothelioma and response to savolitinib: a case report
Translational Lung Cancer Research 2026 March 23 [Link] Yueying Chen, Mengyi Shen, Jiawen Lv, Yuwen Rui, Chunwei Xu, Dong Wang, Tangfeng Lv Abstract Background: Pleural mesothelioma (PM) is a rare malignancy globally, most frequently associated with alterations in tumor suppressor genes such as NF2, BAP1 and CDKN2A. In contrast, mutations or amplifications of the MET…
Read MoreHormonal Status May Contribute to Sex-Based Survival Differences in Epithelioid Peritoneal Mesothelioma
Annals of Surgical Oncology 2026 March 12 [Link] Kaelyn C Cummins, Olivia Sears, Elio R Bitar, Chengli Shen, Allan Tsung, Samantha M Ruff Abstract Background: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is central to treating patients with epithelioid peritoneal mesothelioma (EPM). Male sex is a negative prognostic factor in mesothelioma, but the reasons…
Read MoreNeoadjuvant Pressurized Intraperitoneal Aerosol Chemotherapy for Conversion to Cytoreductive Surgery in Unresectable Malignant Peritoneal Mesothelioma: A Report of 2 Cases
The American Journal of Case Reports 2026 February [Link] Arnaldo Urbano-Ruiz, Bruna Latronico Palma, Ronaldo Elias Carnut Rego, Daniel Bianqui Guaraldo da Silva, Bianca Fava, Erlan Araujo Falcão , Michelle Louise Rodrigues Barbosa da Silva, Julia Rodrigues Leandro Uliano Abstract BACKGROUND Peritoneal mesothelioma (PM) is the second most common presentation site of malignant mesothelioma. The…
Read MoreSafety of secondary CRS/HIPEC in peritoneal surface malignancies: Insights from a national cohort study
European Journal of Surgical Oncology 2026 January 17 [Link] Lukas Pollmann, Jürgen Zieren, Nicola S Pollmann, Urs Giger-Pabst, Pompiliu Piso, Michael Ströhlein, Nicola Cerasani, Fabian Kockelmann, Maximilian Schmeding Abstract Background: For carefully selected patients with peritoneal surface malignancies (PSMs), secondary cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) can provide similar oncological results as…
Read MoreCytoreductive surgery and HIPEC for multicystic peritoneal mesothelioma: therapeutic approach in a rare benign neoplasm
Journal of Surgical Case Reports 2026 January 8 [Link] Goran Aleksandrić, Nemanja Trifunović, Jovana Trifunović, Sara Filipović, Nebojša Mitrović Abstract Multicystic peritoneal mesothelioma (MCPM) is an uncommon tumor of mesothelial origin, characterized by multiple interconnected cystic spaces and uncertain biological behavior. Although traditionally considered benign, its tendency to recur and occasionally spread within the peritoneal…
Read MoreExpanding the role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A multicenter study on uncommon peritoneal malignancies
World Journal of Clinical Oncology 2025 December 24 [Link] Massimo Framarini, Fabrizio D’Acapito, Piero Vincenzo Lippolis, Andrea Di Giorgio, Daniela Di Pietrantonio, Antonio Sommariva, Paolo Sammartino Abstract Background: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has become an established treatment for selected patients with peritoneal metastases (PM) from colorectal, ovarian, and gastric cancers,…
Read MoreThe INDEPSO-ISPSM Consensus on Peritoneal Malignancies-Diagnosis and Management of Peritoneal Mesothelioma
Indian Journal of Surgical Oncology 2025 December [Link] Ambarish Chatterjee, Ashwin K Rajagopal, Vivekanand Sharma, Niharika Garach, Ninad Katdare, Rohit Kumar, Swapnil Patel, Mukurdipi Ray, Somashekhar Sp, Sanket Mehta, Vivek Sukumar, Aditi Bhatt Abstract We report the results of a consensus exercise covering the basics of management of peritoneal mesothelioma (PeM) (diagnostic evaluation, patient selection…
Read MoreCo-occurrence of peritoneal mesothelioma and genitourinary cancers: a case series with comparative outcomes
Pleura and Peritoneum 2025 November 3 [Link] Emma M Bradley, James L Rogers, Marissa C Kuo, Deepa Magge Abstract Objectives: Peritoneal mesothelioma (PM) shares features with genitourinary (GU) malignancies, including histologic appearance, embryologic origin and genetic predispositions. However, data on their co-occurrence are limited. The study presents a case series of PM patients with associated…
Read More
Skip to content